{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:41:19Z","timestamp":1790383279608,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> No study has evaluated the effectiveness of Adalimumab (ADA) as first-line in treatment-na\u00efve patients with retinal vasculitis due to Beh\u00e7et\u2019s Uveitis (BU).<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To compare the efficacy of ADA plus conventional therapy and conventional therapy alone as initial treatments in na\u00efve BU patients characterized by retinal vasculitis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Medical records of BU patients characterized by retinal vasculitis treated with conventional therapy (CT, refers to glucocorticoid and immunosuppressive agents) alone or ADA plus conventional therapy with at least 6 months of follow-up between February 2015 and June 2020 were analyzed. Only patients who were first diagnosed with BU without previous systemic treatment were reviewed. The retinal vasculitis score based on fluorescein angiography (FA), best-corrected visual acuity, glucocorticoid-sparing effect, the number of relapses and ocular complications were evaluated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 45 patients (87 eyes) were included. Twenty-four patients (55.33%) in the CT group were treated with conventional therapy and 21 patients (46.67%) in the ADA group were treated with ADA plus conventional therapy. The inflammatory parameters improved in both groups. FA scores showed significantly greater improvement in ADA group than CT group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). The median number of relapses was significantly lower, and the duration of remission was longer in ADA group than CT group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). At the last visit, a significantly better BCVA improvement (<jats:italic>p<\/jats:italic> = 0.024), better inflammation control (anterior chamber inflammation <jats:italic>p<\/jats:italic> = 0.017 and vitritis <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and lower daily glucocorticoid dosage (<jats:italic>p<\/jats:italic> = 0.005) were identified in patients received ADA therapy. In CT group, 1 patient suffered hepatitis B and tuberculosis, 1 had growth retardation, 1 patient had with osteoporosis, then followed by other mild AEs (mostly respiratory upper tract infections); while in ADA group, 1 patient experienced a mild pneumonia (<jats:italic>n<\/jats:italic> = 1) while milder AEs were represented mostly by respiratory upper tract infections followed by gastrointestinal discomfort.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> ADA plus conventional therapy achieved superiority over conventional therapy as initial treatment in na\u00efve BU patients with retinal vasculitis.<\/jats:p>","DOI":"10.3389\/fphar.2021.609148","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:56:00Z","timestamp":1624337760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["The Efficacy of Adalimumab as an Initial Treatment in Patients with Beh\u00e7et\u2019s Retinal Vasculitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Shizhao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenru","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41433-019-0693-7","article-title":"Soluble Cytokine Receptor Levels in Aqueous Humour of Patients with Specific Autoimmune Uveitic Entities: sCD30 Is a Biomarker of Granulomatous Uveitis","volume":"34","author":"Abu","year":"2019","journal-title":"Eye (Lond)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/09273940591003828","article-title":"Retinal Vasculitis","volume":"13","author":"Abu El-Asrar","year":"2005","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","article-title":"Intraocular Cytokine Environment in Active Beh\u00e7et Uveitis","volume":"142","author":"Ahn","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/09273948.2019.1644351","article-title":"Recovery of the Ellipsoid and Interdigitation Zones in Acute Behcet\u2019s Uveitis after Therapy","volume":"28","author":"Al-Fakhri","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/bjophthalmol-2013-303443","article-title":"The Course of Retinal Vasculitis","volume":"98","author":"Ali","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical Experience with Adalimumab in the Treatment of Ocular Beh\u00e7et Disease","volume":"18","author":"Bawazeer","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and Visual Prognosis in Behcet's Disease","volume":"70","author":"Benezra","year":"1986","journal-title":"Br. J. Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 Therapy in Patients with Refractory Uveitis Due to Beh\u00e7et's Disease: a 1-year Follow-Up Study of 124 Patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: a Global Perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3341\/kjo.1989.3.1.33","article-title":"Clinical Analysis of Uveitis","volume":"3","author":"Chung","year":"1989","journal-title":"Korean J. Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1756-185x.12691","article-title":"Adult Behcet's Disease in Iran: Analysis of 6075 Patients","volume":"19","author":"Davatchi","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor Necrosis Factor \u03b1 Blockers and Malignancy in Children: Forty-Eight Cases Reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of Refractory Uveitis with Adalimumab: a Prospective Multicenter Study of 131 Patients","volume":"119","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine Profiles in Aqueous Humor of Patients with Different Clinical Entities of Endogenous Uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin. Immunol."},{"key":"B15","first-page":"478","article-title":"Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy","volume":"19","author":"Fabiani","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s10067-018-4133-z","article-title":"Efficacy of Adalimumab and Infliximab in Recalcitrant Retinal Vasculitis Inadequately Responsive to Other Immunomodulatory Therapies","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","article-title":"Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Beh\u00e7et's Disease","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative Retention Rate of Adalimumab in Patients with Beh\u00e7et's Disease-Related Uveitis: a Four-Year Follow-Up Study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and Safety of Adalimumab in Beh\u00e7et's Disease-Related Uveitis: a Multicenter Retrospective Observational Study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11739-017-1691-z","article-title":"Quality of Life Impairment in Beh\u00e7et's Disease and Relationship with Disease Activity: a Prospective Study","volume":"12","author":"Fabiani","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12969-019-0333-6","article-title":"Early Administration of Adalimumab for Paediatric Uveitis Due to Beh\u00e7et's Disease","volume":"17","author":"Hiyama","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-019-0181-z","article-title":"Experience of Using Adalimumab in Treating Sight-Threatening Paediatric or Adolescent Behcet's Disease-Related Uveitis","volume":"9","author":"Ho","year":"2019","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related Patterns of Glucocorticoid-Induced Side Effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/s0002-9394(00)00659-0","article-title":"Guidelines for the Use of Immunosuppressive Drugs in Patients with Ocular Inflammatory Disorders: Recommendations of an Expert Panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/nejmoa011110","article-title":"Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor \u03b1-Neutralizing Agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reuma.2019.03.002","article-title":"Quality of Life in Patients with Beh\u00e7et Disease and its Relation with Clinical Symptoms and Disease Activity","volume":"17","author":"Khabbazi","year":"2019","journal-title":"Reumatol Clin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","article-title":"Ocular Features of Behcet's Disease: an International Collaborative Study","volume":"91","author":"Kitaichi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/bf01007830","article-title":"Characteristics of Endogenous Uveitis in Hokkaido, Japan","volume":"235","author":"Kotake","year":"1997","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/s0002-9440(10)64913-9","article-title":"Nitric Oxide Mediates Apoptosis through Formation of Peroxynitrite and Fas\/Fas-Ligand Interactions in Experimental Autoimmune Uveitis","volume":"160","author":"Liversidge","year":"2002","journal-title":"Am. J. Pathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0161-6420(85)34001-0","article-title":"Standardizatlon of Vitreal Inflammatory Activity in Intermediate and Posterior Uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term Side Effects of Glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-014-8425-z","article-title":"Ocular Involvement of Beh\u00e7et's Syndrome: a Comprehensive Review","volume":"49","author":"Ozyazgan","year":"2015","journal-title":"Clinic Rev. Allerg Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the Treatment of Behcet's Disease: Experience in 19 Patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatology"},{"key":"B35","first-page":"20","article-title":"Prognosis in Behcet's Disease","volume":"17","author":"Pivetti Pezzi","year":"1985","journal-title":"Ann. Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bjo.2006.101576","article-title":"Photoreceptor Mitochondrial Oxidative Stress in Early Experimental Autoimmune Uveoretinitis","volume":"91","author":"Rajendram","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s1350-9462(99)00003-8","article-title":"Free Radical Mediated Photoreceptor Damage in Uveitis","volume":"19","author":"Rao","year":"2000","journal-title":"Prog. Retin. Eye Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of Safety of Non-biologic and Biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","article-title":"Visual Acuities \u201chand Motion\u201d and \u201ccounting Fingers\u201d Can Be Quantified with the Freiburg Visual Acuity Test","volume":"47","author":"Schulze-Bonsel","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2017.02.028","article-title":"Clinical Outcome of Retinal Vasculitis and Predictors for Prognosis of Ischemic Retinal Vasculitis","volume":"177","author":"Sharief","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory Neurological Disease in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6872402","article-title":"Long-Term Outcomes of Beh\u00e7et's Syndrome-Related Uveitis: A Monocentric Italian Experience","volume":"2020","author":"Sota","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1515\/9780824865610-005","article-title":"Qualitative Study: the Experience and Impact of Living with Behcet's Syndrome","volume":"130","author":"Tai","year":"2017","journal-title":"N. Z. Med. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/icu.0000000000000562","article-title":"Biologics for the Treatment of Noninfectious Uveitis","volume":"30","author":"Thomas","year":"2019","journal-title":"Curr. Opin. Ophthalmol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10792-008-9263-x","article-title":"Scoring of Dual Fluorescein and ICG Inflammatory Angiographic Signs for the Grading of Posterior Segment Inflammation (Dual Fluorescein and ICG Angiographic Scoring System for Uveitis)","volume":"30","author":"Tugal-Tutkun","year":"2010","journal-title":"Int. Ophthalmol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of Anti-TNF Alpha in Severe And\/or Refractory Beh\u00e7et's Disease: Multicenter Study of 124 Patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1076\/ocii.11.4.277.18260","article-title":"Changing Patterns of Intraocular Inflammatory Disease in Japan","volume":"11","author":"Wakabayashi","year":"2003","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the Treatment Results for Beh\u00e7et Uveitis in Patients Treated with Infliximab and Interferon","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","article-title":"Clinical Features of Chinese Patients with Beh\u00e7et's Disease","volume":"115","author":"Yang","year":"2008","journal-title":"Ophthalmology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/02713680500263606","article-title":"Clinical Patterns and Characteristics of Uveitis in a Tertiary center for Uveitis in China","volume":"30","author":"Yang","year":"2005","journal-title":"Curr. Eye Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00006982-200206000-00012","article-title":"Aqueous Humor Nitric Oxide Levels in Patients with Beh\u00e7et Disease","volume":"22","author":"Yilmaz","year":"2002","journal-title":"Retina"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.609148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:56:04Z","timestamp":1624337764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.609148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":53,"alternative-id":["10.3389\/fphar.2021.609148"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.609148","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"article-number":"609148"}}